C-12蛋白芯片在非小细胞肺癌诊断中的应用  

Clinical Application of C-12 to Diagnosis of NSCLC

作　　者：梁永福[1] 司华[1] 胡荣波[1] 

机构地区：[1]河南省南阳市第二人民医院心外科,473012

出　　处：《医学信息（下旬刊）》2010年第9期117-117,119,共2页Medical information

摘　　要：目的：探讨C-12蛋白芯片（C-12）对NSCLC的诊断价值及其与TNM分期的相关性.方法：1.用C-12蛋白芯片检测系统分别检测实验组116例NSCLC、对照组21例肺良性病变和125例健康者血清中12种肿瘤标志物的水平,分别计算出NSCLC组、肺良性病变组及健康组C-12的阳性率,同时计算出NSCLC不同TNM分期的C-12的阳性率.结果：1. NSCLC组的C-12阳性率为70.18%,显著高于对照组.NSCLC组不同TNM分期间C-12阳性率差异有显著性,Ⅰ＋Ⅱ期阳性率最低,IV期阳性率最高;不同分期之间CA199、CEA、CA242及CA125血清水平差异有显著性.结论：C-12蛋白芯片检测系统对NSCLC具有重要的辅助诊断价值,与NSCLC的TNM分期具有较好的相关性,对TNM分期亦有一定的参考价值.Objective： To evaluate the diagnostic values of 12--tumor-marker protein biochip （C--12） for NSCLC, to study the correlation between C--12 and TNM staging in NSCLC. Methods： 1. The serum levels of 12 tumor markers were measured in 116 cases with NSCLC as trial group, 21 cases with benign pulmonary lesion and 125 healthy individuals as control groups by the C--12 detective system, to calculate the positive rate of C- 12 in NSCLC group, benign pulmonary lesion group, healthy group, and TNM staging of NSCLC respectively. Results： 1. The positive rates of C--12 were 70.18% in NSCLC group. The NSCLC group had significantly higher positive rate than that of the control groups;There was significant difference of positive rate in various clinical stages of NSCLC, the positive rate was lower in I ＋II stage, higher in IV stage; There was significant difference of serum CAJ99,CEA,CA242.and CA125 levels in various clinical stages of NSCLC. Conclusion： The 12--tumor--marker protein biochip detective system possesses important clinical reference value in diagnosis of NSCLC;it is relative to TNM staging in NSCLC ,and is useful in staging NSCLC.

关 键 词：肺癌 非小细胞肺癌 肿瘤标志物 蛋白芯片检测系统 

分 类 号：R734.2[医药卫生—肿瘤]